Published in Clin Med Insights Oncol on April 27, 2015
The Inflammation Response to DEHP through PPARγ in Endometrial Cells. Int J Environ Res Public Health (2016) 0.75
Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor γ-independent mechanism. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev (1995) 13.66
DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet (2001) 10.77
The role of autophagy in cancer development and response to therapy. Nat Rev Cancer (2005) 8.18
Lysosomes and autophagy in cell death control. Nat Rev Cancer (2005) 5.47
Cell biology: autophagy and cancer. Nature (2007) 4.40
Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest (2004) 3.92
PPAR gamma and human metabolic disease. J Clin Invest (2006) 3.83
Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res (2008) 2.15
Endometrial carcinoma. Annu Rev Pathol (2007) 2.13
Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol (2004) 2.08
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer (2012) 2.06
Use of metformin in polycystic ovary syndrome. Am J Obstet Gynecol (2008) 1.92
Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care (2011) 1.83
T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem (2002) 1.75
The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer (2006) 1.55
Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer (2004) 1.52
Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem (2002) 1.48
The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update (2004) 1.43
Nuclear hormone receptors enable macrophages and dendritic cells to sense their lipid environment and shape their immune response. Physiol Rev (2012) 1.38
Peroxisome proliferator-activated receptors (PPARs) and ovarian function--implications for regulating steroidogenesis, differentiation, and tissue remodeling. Reprod Biol Endocrinol (2005) 1.36
Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer (2001) 1.23
Dual activation of PPARalpha and PPARgamma by mono-(2-ethylhexyl) phthalate in rat ovarian granulosa cells. Mol Cell Endocrinol (2003) 1.13
Biologic markers in endometrial cancer treatment. APMIS (2009) 1.12
15-Deoxy-Delta(12,14)-prostaglandin J(2), a ligand for peroxisome proliferator-activated receptor-gamma, induces apoptosis in JEG3 choriocarcinoma cells. Biochem Biophys Res Commun (1999) 1.11
Apoptotic signaling in polyamine analogue-treated SK-MEL-28 human melanoma cells. Cancer Res (2001) 1.10
Disruption of PPARgamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy. Cell Death Differ (2009) 1.10
PPAR gamma represses VEGF expression in human endometrial cells: implications for uterine angiogenesis. Angiogenesis (2006) 1.09
Expression and localization of PPARs in the rat ovary during follicular development and the periovulatory period. Endocrinology (2001) 1.08
Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am (1999) 1.05
Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. Neoplasia (2006) 1.04
PPARgamma inhibitors reduce tubulin protein levels by a PPARgamma, PPARdelta and proteasome-independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells. Int J Cancer (2007) 1.03
Can PPAR gamma ligands be used in cancer therapy? Curr Med Chem Anticancer Agents (2004) 1.01
The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells. Biotechnol Adv (2011) 0.98
Biological significance and therapeutic implication of resveratrol-inhibited Wnt, Notch and STAT3 signaling in cervical cancer cells. Genes Cancer (2014) 0.98
Functional regulatory role of STAT3 in HPV16-mediated cervical carcinogenesis. PLoS One (2013) 0.97
PPAR-gamma decreases endometrial stromal cell transcription and translation of RANTES in vitro. J Clin Endocrinol Metab (2002) 0.94
Cell-specific conditional deletion of Pten in the uterus results in differential phenotypes. Gynecol Oncol (2011) 0.94
Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-γ (PPAR-γ): at the cross-road of pancreatic cancer cell proliferation. Biochim Biophys Acta (2013) 0.93
Clinical implication of expression of cyclooxygenase-2 and peroxisome proliferator activated-receptor gamma in epithelial ovarian tumours. Br J Cancer (2004) 0.93
Peroxisome proliferator-activated receptor-gamma agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines. Int J Gynecol Cancer (2007) 0.93
Expression and functional role of peroxisome proliferator-activated receptor-gamma in ovarian folliculogenesis in the sheep. Biol Reprod (2003) 0.92
Autophagy in nuclear receptor PPARgamma-deficient mouse prostatic carcinogenesis. Autophagy (2010) 0.91
Dual repressive effect of angiotensin II-type 1 receptor blocker telmisartan on angiotensin II-induced and estradiol-induced uterine leiomyoma cell proliferation. Hum Reprod (2007) 0.91
Peroxisome proliferator-activated receptor gamma and growth inhibition by its ligands in uterine endometrial carcinoma. Clin Cancer Res (2006) 0.88
Inhibition of peroxisome proliferator-activated receptor gamma activity suppresses pancreatic cancer cell motility. Cancer Sci (2008) 0.88
Apoptosis, proliferation, and hormone receptors in endometrial carcinoma: results depending on methods of analysis. Int J Oncol (2003) 0.87
PPAR Gamma: Coordinating Metabolic and Immune Contributions to Female Fertility. PPAR Res (2008) 0.86
Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines. J Cancer Res Clin Oncol (2010) 0.85
The gene for aromatase, a rate-limiting enzyme for local estrogen biosynthesis, is a downstream target gene of Runx2 in skeletal tissues. Mol Cell Biol (2010) 0.85
Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers. J Cancer Res Clin Oncol (2011) 0.85
Anticancer effects of 15d-prostaglandin-J2 in wild-type and doxorubicin-resistant ovarian cancer cells: novel actions on SIRT1 and HDAC. PLoS One (2011) 0.84
Down-regulation of peroxisome proliferator-activated receptor gamma in human cervical carcinoma. Gynecol Oncol (2005) 0.84
Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner. PLoS One (2011) 0.84
PPARalpha signaling mediates the synergistic cytotoxicity of clioquinol and docosahexaenoic acid in human cancer cells. Biochem Pharmacol (2009) 0.82
Sperm metabolism in pigs: a role for peroxisome proliferator-activated receptor gamma (PPARγ). J Exp Biol (2012) 0.82
Telmisartan induces growth inhibition, DNA double-strand breaks and apoptosis in human endometrial cancer cells. PLoS One (2014) 0.80
The defect of Ku70 affects sensitivity to x-ray and radiation-induced caspase-dependent apoptosis in lung cells. J Vet Med Sci (2012) 0.80
Idealized PPARγ-Based Therapies: Lessons from Bench and Bedside. PPAR Res (2012) 0.80
Effects of low-dose metformin and rosiglitazone on biochemical, clinical, metabolic and biophysical outcomes in polycystic ovary syndrome. J Obstet Gynaecol (2013) 0.80
Hsp90 modulates PPARγ activity in a mouse model of nonalcoholic fatty liver disease. J Lipid Res (2014) 0.78
An attempt at conservative treatment in selected cases of type I endometrial carcinoma (stage I a/G1) in young women. Eur J Gynaecol Oncol (2009) 0.77
Re: Henderson,B.E. and Feigelson,H.S. (2000) hormonal carcinogenesis. Carcinogenesis, 21, 427-433. Carcinogenesis (2001) 0.77
[Proliferation and apoptosis effect of rosiglitazone on human ovarian cancer cell line SKOV3]. Sichuan Da Xue Xue Bao Yi Xue Ban (2009) 0.76
In vitro effect of peroxisome proliferator activated receptor (PPAR) ligands on prostaglandin E2 synthesis and secretion by porcine endometrium during the estrous cycle and early pregnancy. J Physiol Pharmacol (2013) 0.76
5-(Hydroxymethyl)-2-furaldehyde inhibits adipogenic and enhances osteogenic differentiation of rat bone mesenchymal stem cells. Nat Prod Commun (2014) 0.76